Orlistat / MAPK Cancer Research Results

OLST, Orlistat: Click to Expand ⟱

Features:

Orlistat (tetrahydrolipstatin; anti-obesity drug; OTC 60 mg, Rx 120 mg). A potent, minimally absorbed gastrointestinal lipase inhibitor that reduces dietary fat absorption (~30% at 120 mg TID).

Primary mechanisms (conceptual rank):
1) Irreversible inhibition of gastric + pancreatic lipases (↓ triglyceride hydrolysis)
2) ↓ Chylomicron formation → ↓ systemic lipid flux
3) Secondary metabolic shifts (weight loss–mediated insulin sensitivity changes)

Bioavailability / PK relevance: Very low systemic absorption (<1%); primary action is intraluminal in gut. Most systemic mechanistic cancer data derive from higher in-vitro concentrations or off-target effects (e.g., FASN inhibition).

In-vitro vs oral exposure: Many anti-cancer studies use concentrations likely exceeding achievable plasma levels from standard dosing (qualifier: high concentration only for direct tumor cytotoxicity).

Clinical evidence status: Approved for obesity; cancer evidence largely preclinical/observational; no robust oncology RCT indication.

Inhibits lipase and is used to facilitate weight loss.

Orlistat — Cancer vs Normal Cell Pathway Map

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Fatty Acid Synthase (FASN)	↓ (high concentration only)	↔ (low FASN dependence)	R/G	Lipid synthesis blockade; apoptosis	Well-known off-target in vitro; many tumors overexpress FASN. Clinical relevance limited by low systemic exposure.
2	Lipid availability / metabolic flux	↓ (indirect)	↓ (systemic)	G	Reduced lipid supply	Weight-loss–mediated effect; may indirectly reduce pro-tumor metabolic signaling (insulin/IGF axis).
3	PI3K/AKT/mTOR	↓ (model-dependent)	↔ / ↓ (metabolic improvement)	R/G	Reduced anabolic signaling	Often secondary to lipid stress or metabolic shifts; not primary gut mechanism.
4	Apoptosis (caspase activation)	↑ (high concentration only)	↔	R/G	Programmed cell death	Observed in cancer lines at supra-physiologic levels; translation uncertain.
5	ROS / lipid peroxidation stress	↑ (lipid stress–related; model-dependent)	↔	P/R	Metabolic oxidative stress	Linked to FASN inhibition; not central to approved mechanism.
6	NRF2 axis	↔ (insufficient evidence)	↔	R/G	Not a dominant axis	No consistent evidence of primary NRF2 modulation at therapeutic exposure.
7	Ferroptosis (lipid metabolism link)	↑ (theoretical / model-dependent)	↔	R/G	Lipid vulnerability shift	FASN inhibition could alter lipid composition; ferroptosis relevance remains investigational.
8	HIF-1α / Warburg coupling	↓ (indirect; metabolic improvement)	↔	G	Reduced pro-growth metabolic signaling	Likely secondary to weight loss and insulin reduction rather than direct tumor action.
9	Ca²⁺ signaling	↔	↔	P/R	No primary role	Not a recognized mechanistic axis for orlistat.
10	Clinical Translation Constraint	↓ (constraint)	↓ (constraint)	—	Minimal systemic exposure	Low absorption limits direct anti-tumor applicability; GI side effects and fat-soluble vitamin malabsorption noted.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr

MAPK, mitogen-activated protein kinase: Click to Expand ⟱

Source: CGL-CS

Type:

Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death).

MAPK Pathways: The MAPK family includes several pathways, the most notable being:
1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival.
2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis.
3.p38 MAPK: Associated with inflammatory responses and apoptosis.

Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations.
Altered Expression Levels:
Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival.
Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling.
The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers.

Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion.

Scientific Papers found: Click to Expand⟱

1225-

OLST,

Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway

vitro+vivo,

PC,

TumCMig↓, TumCI↓, Ferroptosis↑, MAPK↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,

Cell Death ⓘ

Ferroptosis↑, 1, MAPK↓, 1,

Migration ⓘ

TumCI↓, 1, TumCMig↓, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: MAPK, mitogen-activated protein kinase

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:14  Target#:181  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid